ArticlesThe art of communication for leaders: the essence of effective leadership
ArticlesGenAI - reluctance versus opportunity: What do Romanian company leaders expect?
InterviewsHow do we evaluate shares in 2024? Opportunities vs. risks
InterviewsStrauss Romania: Evolving the consumers coffee experience is crucial
InterviewsA long term partnership is better than the commercial value of a deal
NewsThe new Lexus LBX, a revolutionary compact crossover, is available in Romania
NewsSchneider Electric announces the winners of the Sustainability Impact Awards 2023 in Romania
Big pharmas, largely absent over the past few years, played a bigger role in 2014’s pyrotechnics, spending nearly US$90 billion on M&A to close — or attempt to close — “growth gaps”.
While big pharmas were mostly focused on creating strategic franchises, specialty pharmas pursued transactions that provided the scale to compete globally. Whatever you thought of specialty pharmas’ actions — destiny made manifest or mere hubris — the resulting fi repower fi reworks, worth more than US$130 billion, were impossible to ignore.
For complete information, please see the attached report, or the Romanian version of the article, here.
